Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.suvenpharm.com | |
Market Cap | 16,209.42 Cr. | |
Enterprise Value(EV) | 16,197.75 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 14.57 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 43.71 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.22 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 77.86 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 8.18 | Calculated using Price: 636.75 |
Dividend Yield | 0.94 | Period Ending 2023-03 |
No. of Shares Subscribed | 25.46 Cr. | 254,564,956 Shares |
FaceValue | 1 | |
About Suven Pharmaceuticals Ltd. | ||
The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. |
1 Day |
|
-0.52% |
1 Week |
|
+0.61% |
1 Month |
|
-1.83% |
3 Month |
|
-6.86% |
6 Month |
|
+11.48% |
1 Year |
|
+35.37% |
2 Year |
|
+11.20% |
5 Year |
|
|
10 Year |
|
5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 18.92 | 44.58 | 35.78 | 33.52 | 25.21 | |
Return on Capital Employed (%) | 23.87 | 50.21 | 40.76 | 45.92 | 33.41 | |
Return on Assets (%) | 13.39 | 30.07 | 25.26 | 25.62 | 20.18 |
Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 590 | 845 | 1,181 | 1,527 | 1,735 | 1,935 | |
Non Curr. Liab. | 35 | 128 | 74 | 92 | 72 | 72 | |
Curr. Liab. | 191 | 320 | 322 | 348 | 303 | 112 | |
Minority Int. | |||||||
Equity & Liab. | 816 | 1,292 | 1,576 | 1,967 | 2,110 | 2,120 | |
Non Curr. Assets | 393 | 781 | 910 | 702 | 955 | 951 | |
Curr. Assets | 423 | 511 | 667 | 1,265 | 1,155 | 1,169 | |
Misc. Exp. not W/O | |||||||
Total Assets | 816 | 1,292 | 1,576 | 1,967 | 2,110 | 2,120 |
Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,168 | |
Other Income | 1 | 18 | 14 | 92 | 46 | 56 | |
Total Income | 378 | 852 | 1,024 | 1,413 | 1,387 | 1,224 | |
Total Expenditure | -206 | -449 | -567 | -739 | -766 | -669 | |
PBIDT | 172 | 403 | 457 | 674 | 620 | 555 | |
Interest | -3 | -23 | -12 | -9 | -13 | -5 | |
Depreciation | -12 | -24 | -32 | -39 | -48 | -49 | |
Taxation | -49 | -88 | -105 | -214 | -148 | -130 | |
Exceptional Items | |||||||
PAT | 109 | 317 | 362 | 454 | 411 | 371 | |
Minority Interest | |||||||
Share Associate | |||||||
Other Related Items | |||||||
Consolidated Net Profit | 109 | 317 | 362 | 454 | 411 | 371 | |
Adjusted EPS | 12 | 14 | 18 | 16 | 15 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 50 | 407 | 383 | 330 | 451 | |
Cash Fr. Inv. | -65 | -413 | -311 | -136 | -195 | |
Cash Fr. Finan. | 26 | 7 | -76 | -156 | -236 | |
Net Change | 11 | 1 | -5 | 37 | 20 | |
Cash & Cash Eqvt | 11 | 12 | 7 | 45 | 65 |
Wed, 10 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018 Suven Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
Mon, 01 Apr 2024
Trading Window-XBRL SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Closure of Trading Window |
Sat, 30 Mar 2024
Trading Window Suven Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
Wed, 24 Apr 2024 |
High Increase in 1 Year |
5 SMA Crossing 20 SMA From Below |
RSI Trending Down |
MFI Trending Up |
Close Crossing 20 SMA From Above |